Home > About Us
Celentyx Ltd is a CRO offering bespoke assay services in human immunology, including immuno-oncology, autoimmunity & inflammation, fibrosis and neuroinflammation.
Drawing on the World-leading expertise of Celentyx personnel, along with our close association with the MRC Centre for Immune Regulation and the Centre for Translational Inflammation Research enables the human immune system in health and disease to be investigated at the highest levels of resolution.
Drawing on the World-leading expertise of Celentyx personnel, along with our close association with the MRC Centre for Immune Regulation and the Centre for Translational Inflammation Research enables the human immune system in health and disease to be investigated at the highest levels of resolution.
Key Facts:
- Founded in 2007
- Located in Birmingham, UK
- Founding scientists Professors Nicholas Barnes and John Gordon
- Scientific staff PhD qualified
- Benefitting from strategic relationships with:
|
|
|
Celentyx was founded in 2006 by Professors Nicholas Barnes and John Gordon to translate the ground-breaking research from the MRC Centre for Immune Regulation at the University of Birmingham into a drug discovery setting.
Nicholas Barnes is the principal founder and CEO of Celentyx. He has an international reputation for his applied research in neuropharmacology and brings to Celentyx his proven track record in the investigation of potential drug targets and the delivery of candidate therapeutics. This experience helps to provide a service to our clients with an appreciation of the requirements and challenges of drug development.
John Gordon is a co-founder and CSO of Celentyx Ltd. He is an internationally recognised authority on immune cell biology and immune cell-mediated diseases. He is one of the world’s most highly cited researchers (www.ISIHighlyCited.com) and has a proven track record in the successful application of research within the field of translational medicine delivering relevant data sets supporting development of projects with immune system and immuno-oncology relevant indications.
The combination of these two spheres of expertise allow us to provide a service to our pharmaceutical and biotech clients to accelerate their development of immuno-oncology therapeutics. We benefit from the world-leading expertise of the neighbouring MRC Centre for Immune Regulation and Institute of Translational Medicine (Birmingham, UK). Our propritary assays support clients in candidate selection, medium-throughput screening, differentiation, mechanism of action, target discovery and deconvolution and proof of concept studies.
Nicholas Barnes is the principal founder and CEO of Celentyx. He has an international reputation for his applied research in neuropharmacology and brings to Celentyx his proven track record in the investigation of potential drug targets and the delivery of candidate therapeutics. This experience helps to provide a service to our clients with an appreciation of the requirements and challenges of drug development.
John Gordon is a co-founder and CSO of Celentyx Ltd. He is an internationally recognised authority on immune cell biology and immune cell-mediated diseases. He is one of the world’s most highly cited researchers (www.ISIHighlyCited.com) and has a proven track record in the successful application of research within the field of translational medicine delivering relevant data sets supporting development of projects with immune system and immuno-oncology relevant indications.
The combination of these two spheres of expertise allow us to provide a service to our pharmaceutical and biotech clients to accelerate their development of immuno-oncology therapeutics. We benefit from the world-leading expertise of the neighbouring MRC Centre for Immune Regulation and Institute of Translational Medicine (Birmingham, UK). Our propritary assays support clients in candidate selection, medium-throughput screening, differentiation, mechanism of action, target discovery and deconvolution and proof of concept studies.